Cargando…

GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR)-activating mutation predicts excellent response to EGFR tyrosine kinase inhibitors (TKIs). However, lung cancer patients are often with unknown EGFR mutation status because there are little tumor specimen to determine. TKIs induce tum...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000015/
https://www.ncbi.nlm.nih.gov/pubmed/24758907
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.06
_version_ 1783331589983305728
collection PubMed
description BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR)-activating mutation predicts excellent response to EGFR tyrosine kinase inhibitors (TKIs). However, lung cancer patients are often with unknown EGFR mutation status because there are little tumor specimen to determine. TKIs induce tumor cell apoptosis which associates with several apoptosis-related genes. To explore the association between GNAS1 T393C polymorphism and therapeutic efficacy of TKI in pretreated advanced non-small cell lung cancer (NCSLC) with unknown EGFR mutation status. METHODS: A total of 116 patients were recruited for the study from Zhejiang Cancer Hospital, all of whom were treated with gefitinib or erlotinib after failure to prior chemotherapy. We detected the genotype of peripheral blood lymphocytes of patients with GNAS1 T393C polymorphism through polymerase chain reaction (PCR). Statistical analysis was performed by SPSS version 18.0. RESULTS: The overall response rate was 29.3%. No significant associations were found among GNAS1 T393C polymorphism and the objective response rate. The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P < 0.001, P < 0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). CONCLUSION: Our data suggest the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.
format Online
Article
Text
id pubmed-6000015
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60000152018-07-06 GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR)-activating mutation predicts excellent response to EGFR tyrosine kinase inhibitors (TKIs). However, lung cancer patients are often with unknown EGFR mutation status because there are little tumor specimen to determine. TKIs induce tumor cell apoptosis which associates with several apoptosis-related genes. To explore the association between GNAS1 T393C polymorphism and therapeutic efficacy of TKI in pretreated advanced non-small cell lung cancer (NCSLC) with unknown EGFR mutation status. METHODS: A total of 116 patients were recruited for the study from Zhejiang Cancer Hospital, all of whom were treated with gefitinib or erlotinib after failure to prior chemotherapy. We detected the genotype of peripheral blood lymphocytes of patients with GNAS1 T393C polymorphism through polymerase chain reaction (PCR). Statistical analysis was performed by SPSS version 18.0. RESULTS: The overall response rate was 29.3%. No significant associations were found among GNAS1 T393C polymorphism and the objective response rate. The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P < 0.001, P < 0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). CONCLUSION: Our data suggest the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor. 中国肺癌杂志编辑部 2014-04-20 /pmc/articles/PMC6000015/ /pubmed/24758907 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.06 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title_full GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title_fullStr GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title_full_unstemmed GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title_short GNAS1基因T393C多态性与EGFR突变状态未明复治晚期非小细胞肺癌TKI疗效的关联研究
title_sort gnas1基因t393c多态性与egfr突变状态未明复治晚期非小细胞肺癌tki疗效的关联研究
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000015/
https://www.ncbi.nlm.nih.gov/pubmed/24758907
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.06
work_keys_str_mv AT gnas1jīyīnt393cduōtàixìngyǔegfrtūbiànzhuàngtàiwèimíngfùzhìwǎnqīfēixiǎoxìbāofèiáitkiliáoxiàodeguānliányánjiū
AT gnas1jīyīnt393cduōtàixìngyǔegfrtūbiànzhuàngtàiwèimíngfùzhìwǎnqīfēixiǎoxìbāofèiáitkiliáoxiàodeguānliányánjiū
AT gnas1jīyīnt393cduōtàixìngyǔegfrtūbiànzhuàngtàiwèimíngfùzhìwǎnqīfēixiǎoxìbāofèiáitkiliáoxiàodeguānliányánjiū
AT gnas1jīyīnt393cduōtàixìngyǔegfrtūbiànzhuàngtàiwèimíngfùzhìwǎnqīfēixiǎoxìbāofèiáitkiliáoxiàodeguānliányánjiū
AT gnas1jīyīnt393cduōtàixìngyǔegfrtūbiànzhuàngtàiwèimíngfùzhìwǎnqīfēixiǎoxìbāofèiáitkiliáoxiàodeguānliányánjiū